Why Should You Attend:
The EMA (European Medicines Agency) developed a regulatory framework that became part of EU legislation in 2004. Other jurisdictions later copied all or parts of the regulations, but the US took until 2011 to catch up with its own legal framework. This helped to kick-start the market for biosimilars in Europe ahead of most other parts of the world.
The early years of the biosimilars industry resembled the history of the generics industry. A combination of lack of familiarity with the concept of biosimilars, initially slow adoption and a fight back by the originators all contributed to slow progress. The problems faced by the pioneers included pricing, Interchangeability and public policy regarding biosimilars.
The webinar looks at how the pioneers dealt with these issues, the degree to which these problems still exist, how companies have devised ways to deal with them and what attendees can learn from this experience and use to their own advantage.
It is easy for new entrants to the biosimilars market to make mistakes that can be costly. For instance - to assume that all the European markets are the same since they are governed by the same regulatory rules.
It is also easy to assume that the biosimilars market is simply the younger brother of the generics industry and that what works in the one can just be copied to the other.
Sadly, life and the biosimilars market are not that simple! Assumptions like these can lead to serious (and expensive) problems.
Learn from this webinar how the companies operating in the European biosimilars market found ways to deal with the issues of what level to price their products, Interchangeability, government and healthcare providers’ policies and how you can apply these lessons to your own plans for European market entry.
Areas Covered in the Webinar:
Who Will Benefit:
From industries including:
Peter Wittner, B.Sc., is an independent consultant specialising in the commercial aspects of generics with more than 30 years’ pharmaceutical experience. Before starting his own business, Peter headed the European sales and marketing departments of the UK generics companies Evans Medical and H.N. Norton, which later became part of IVAX.
He later joined the Indian generic leader Ranbaxy as Managing Director to help set up its UK business and then returned to consultancy work. Peter is a regular speaker and trainer on topics related to generics and biosimilars.
His company Interpharm works with new market entrants on generic strategies, assists in business development for generic companies based outside the EU that are trying to enter the market and advises companies that are seeking to enlarge their product range.
While mainly oriented to the commercial side with services such as market intelligence and pricing overviews for example, Interpharm also advises on IP and patent issues as well as the legal background to the pharmaceutical industry in Europe and the US. In addition, Peter has increasingly become involved with biosimilars and has frequently spoken on the topic and run seminars on the subject.
On the other side of the equation, Interpharm has also worked with originator companies that are concerned with defending their major brands from generic incursion.
Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time.If you have any concern about the content of the webinar and not satisfied please contact us at below email or by call mentioning your feedback for resolution of the matter. We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email [email protected] call +1-888-717-2436 (Toll Free).
PAYMENT METHOD: 100% Secure Transaction